Related Experiment Video
Updated: May 11, 2026

Permanent Cerebral Vessel Occlusion via Double Ligature and Transection
Published on: July 21, 2013
Role of matrix metalloproteinases in delayed cortical responses after stroke
Bing-Qiao Zhao1, Sophia Wang, Hahn-Young Kim
1Neuroprotection Research Laboratory, Department of Radiology, Massachusetts General Hospital, MGH East 149-2401, Charlestown, Massachusetts 02129, USA.
Abstract:
Matrix metalloproteinases (MMPs) are zinc-endopeptidases with multifactorial actions in central nervous system (CNS) physiology and pathology. Accumulating data suggest that MMPs have a deleterious role in stroke. By degrading neurovascular matrix, MMPs promote injury of the blood-brain barrier, edema and hemorrhage. By disrupting cell-matrix signaling and homeostasis, MMPs trigger brain cell death. Hence, there is a movement toward the development of MMP inhibitors for acute stroke therapy. But MMPs may have a different role during delayed phases after stroke. Because MMPs modulate brain matrix, they may mediate beneficial plasticity and remodeling during stroke recovery. Here, we show that MMPs participate in delayed cortical responses after focal cerebral ischemia in rats. MMP-9 is upregulated in peri-infarct cortex at 7-14 days after stroke and is colocalized with markers of neurovascular remodeling. Treatment with MMP inhibitors at 7 days after stroke suppresses neurovascular remodeling, increases ischemic brain injury and impairs functional recovery at 14 days. MMP processing of bioavailable VEGF may be involved because inhibition of MMPs reduces endogenous VEGF signals, whereas additional treatment with exogenous VEGF prevents MMP inhibitor-induced worsening of infarction. These data suggest that, contrary to MMP inhibitor therapies for acute stroke, strategies that modulate MMPs may be needed for promoting stroke recovery.
Insights
Matrix metalloproteinases (MMPs) play a beneficial role in stroke recovery by promoting neurovascular remodeling. Inhibiting MMPs during delayed stroke phases worsens brain injury and impairs functional recovery.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Matrix metalloproteinases (MMPs) are enzymes involved in central nervous system (CNS) physiology and pathology.
- MMPs are implicated in stroke, degrading the neurovascular matrix, causing blood-brain barrier injury, edema, and hemorrhage.
- MMP inhibitors are explored for acute stroke therapy, but their role in delayed stroke phases is unclear.
Purpose of the Study:
- To investigate the role of MMPs in delayed cortical responses following focal cerebral ischemia in rats.
- To determine if MMPs contribute to beneficial plasticity and remodeling during stroke recovery.
Main Methods:
- Induction of focal cerebral ischemia in rats.
- Analysis of MMP-9 expression and its colocalization with neurovascular remodeling markers in the peri-infarct cortex at 7-14 days post-stroke.
- Administration of MMP inhibitors at 7 days post-stroke and assessment of neurovascular remodeling, brain injury, and functional recovery at 14 days.
- Evaluation of the involvement of vascular endothelial growth factor (VEGF) signaling.
Main Results:
- MMP-9 was upregulated in the peri-infarct cortex 7-14 days after stroke, co-localizing with neurovascular remodeling markers.
- Treatment with MMP inhibitors at 7 days post-stroke suppressed neurovascular remodeling, exacerbated ischemic brain injury, and impaired functional recovery at 14 days.
- MMP inhibition reduced endogenous VEGF signaling, while exogenous VEGF administration ameliorated the negative effects of MMP inhibitors on infarction.
Conclusions:
- MMPs play a crucial role in mediating beneficial neurovascular remodeling and functional recovery during delayed phases after stroke.
- Targeting MMPs with inhibitors for acute stroke therapy may be detrimental for long-term recovery.
- Strategies modulating MMP activity, rather than inhibition, may be beneficial for promoting stroke recovery.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
A...
Ischemic Stroke ll: Pathophysiology

